The discovery of JAK2 mutations allowed the development of JAK2 inhibitors for target therapies, including ruxolitinib, approved for patients with primary or secondary myelofibrosis and hydroxyurea‐resistant or intolerant PV patients. This evidence concerns the gene JAK2 and myelofibrosis.